Pulmonary fibrosis is an irreversible interstitial lung disease characterized by lung parenchyma remodeling and collagen deposition. In recent years, the incidence and mortality of pulmonary fibrosis caused by unknown causes have risen. However, its pathogenesis is still unclear. C-X-C motif chemokine ligand 12 (CXCL12)/C-X-C chemokine receptor 4 (CXCR4)/CXCR7 signal axis plays a critical regulatory role in pulmonary fibrosis disease. In addition, the signal axis has been shown to regulate recruitment and migration of circulating fibrocytes, mesenchymal stem cells to the damage lung tissue, the migration of endothelial cells, the proliferation and differentiation of fibroblasts and endothelial cells, which further affects the occurrence and progression of pulmonary fibrosis. In this review, we summarized the pathogenesis and treatment research progress of CXCL12 and its receptor CXCR4/CXCR7 in the occurrence and progression of pulmonary fibrosis.
肺纤维化是一种以肺实质重塑和胶原沉积为特征的不可逆性间质性肺病。近年来，不明原因导致的肺纤维化发病率和病死率呈上升趋势，其发病机制目前尚不完全清楚。CXC趋化因子配体12 (C-X-C motif chemokine ligand 12, CXCL12）/CXC趋化因子受体（C-X-C chemokine receptor，CXCR) 4/CXCR7信号轴在肺纤维化疾病中起关键调控作用，可募集循环纤维细胞、间充质干细胞向受损肺组织的迁移，介导内皮细胞的迁移，以及调控成纤维细胞、内皮细胞的增殖与分化，进而影响肺纤维化的发生与进展。本文就CXCL12及其受体CXCR4/CXCR7在肺纤维化中的机制和治疗研究进展予以综述。.
Keywords: C-X-C motif chemokine ligand 12 (CXCL12); Inhibitor; Pulmonary fibrosis; Receptor.